Abstract
B-cell maturation antigen (BCMA) is an ideal target in multiple myeloma (MM) due to highly specific expression in malignant plasma cells. BCMA-directed therapies including antibody drug conjugates, chimeric antigen receptor-T cells and bispecific antibodies (BsAbs) have shown high response rates in MM. WVT078 is an anti-BCMA× anti-CD3 BsAb that binds to BCMA with subnanomolar-affinity. It was selected based on potent T cell activation and anti-MM activity in preclinical models with favorable tolerability in cynomolgus monkey. In the ongoing first-in-human phase I dose-escalation study (NCT04123418), 33 patients received intravenous WVT078 once weekly at escalated dosing. At the active doses of 48–250 µg/kg tested to date (n = 26), the overall response rate (ORR) was 38.5% (90% CI: 22.6–56.4%) and the complete response rate (CRR, stringent complete response + complete response) was 11.5%, (90% CI: 3.2–27.2%). At the highest dose level tested, the ORR was 75% (3 of 4 patients). 26 (78.8%) patients reported at least one Grade ≥3 AE and 16 of these AEs were suspected to be drug related. 20 patients (60.6%) experienced cytokine release syndrome. WVT078 has an acceptable safety profile and shows preliminary evidence of clinical activity at doses tested to date.
Similar content being viewed by others
Data availability
Novartis will not provide access to patient-level data, if there is a reasonable likelihood that individual patients could be re-identified. Phase 1 studies, by their nature, present a high risk of patient re-identification; therefore, patient individual results for phase 1 studies cannot be shared. In addition, clinical data, in some cases, have been collected subject to contractual or consent provisions that prohibit transfer to third parties. Such restrictions may preclude granting access under these provisions. Where co-development agreements or other legal restrictions prevent companies from sharing particular data, companies will work with qualified requestors to provide summary information where possible.
References
Mimura N, Hideshima T, Anderson KC. Novel therapeutic strategies for multiple myeloma. Exp Hematol. 2015;43:732–41.
Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2018;93:981–1114.
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327:464–77.
Avery DT, Kalled SL, Ellyard JI, Ambrose C, Bixler SA, Thien M, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Investig. 2003;112:286–97.
O’Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199:91–8.
Chiu A, Xu W, He B, Dillon SR, Gross JA, Sievers E, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood. 2007;109:729–39.
Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009;16:309–23.
Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821.
Moreaux J, Sprynski AC, Dillon SR, Mahtouk K, Jourdan M, Ythier A, et al. APRIL and TACI interact with syndecan‐1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol. 2009;83:119–29.
Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, et al. γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;6:7333.
Ghermezi M, Li M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102:785–95.
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207–21.
Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16.
Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24.
Leblay N, Maity R, Barakat E, McCulloch S, Duggan P, Jimenez-Zeped V. et al. Cite-Seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or BITEs immunotherapy. Blood. 2020;136(Suppl 1):11–12.
Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai Y-T, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12:1–7.
Da Vià MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27:616–9.
Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398:665–74.
Sebag M, Raje NS, Bahlis NJ, Costello C, Dholaria B, Solh M, et al. Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from magnetismm-1. Blood. 2021;138:895.
Zonder JA, Richter J, Bumma N, Brayer J, Hoffman JE, Bensinger WI, et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1/2 first-in-human study in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2021;138:160.
D’Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, et al. Phase I first-in-human study of ABBV-383, a B-cell maturation antigen × CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2022;40:3576–86.
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346.
Clynes RA, Desjarlais JR. Redirected T cell cytotoxicity in cancer therapy. Annu Rev Med. 2019;70:437–50.
Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody em801 for multiple myeloma treatment. Cancer Cell. 2017;31:396–410.
Goldstein RL, Goyos A, Li C-M, Deegen P, Bogner P, Sternjak A, et al. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 2020;4:4180–94.
Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma. J Clin Investig. 2019;129:2210–21.
Saber H, Del Valle P, Ricks TK, Leighton JK, An FDA. oncology analysis of CD3 bispecific constructs and first-in-human dose selection. Regul Toxicol Pharmacol. 2017;90:144–52.
Aung KL, El-Khoueiry AB, Gelmon K, Tran B, Bajaj G, He B, et al. A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours. Investig New Drugs. 2018;36:1026–36.
Cowan AJ, Pont M, Sather BD, Turtle CJ, Till BG, Libby E, et al. Safety and efficacy of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myeloma. Blood. 2021;138:551.
Acknowledgements
The authors thank all the participating sites, the patients participating in this clinical trial, and their families. The authors thank the staff at each participating institution who assisted with the study. The authors thank Gary Vanasse, Ryan Polli, Mirek Dostalek, Bernd Potthoff, Martine Duval, Jeanne Hardy, Carsten Krantz, Sema Kurtulus, Raina Duan, Michelle Coulson, Daher Ibrahim Aibo, Mike Daley, Brian Stoll, Stan Spence, Joni Lam, Melissa Ramones, Connie Hong, Lucia Huang, Brian Holmberg, Na Li, Barbara Brannetti and Gregory Moore for their contribution to the preclinical and clinical research. The authors also wish to thank Glenn Dranoff, Alice Shaw, Lilli Petruzzelli, David Steensma, Ulrich Bialucha, Juliet Williams, John Desjarlais, Francesco Hofmann and Jeffrey Engelman for their feedback and guidance.
Author information
Authors and Affiliations
Contributions
KA, AO, KH, GT, AC and FCB contributed to the design, execution, data analysis and the result interpretation for preclinical studies. KA was responsible for the in vivo studies in mouse models. AO was responsible for the in vitro experiments. KH was responsible for the pharmacology study in cyno monkey. GT was responsible for the GSI combination experiments. AC was responsible for the characterization of binding affinities. FCB was responsible for the bioanalytical analysis. JWB and BG were responsible for the design of the BCMA Ab discovery and optimization campaigns, Ab engineering, data analysis, result interpretation. HL was responsible for the design of the preclinical studies, data analysis and interpretation. HL, BG and JPS led the selection of the lead molecule. SDV designed the clinical study, analyzed, and interpreted clinical data. PEJ analyzed clinical data. AF carried out the clinical study. LF analyzed and help interpreting clinical data. JPS supervised preclinical and clinical activities in the program. MSR, YC, FS, AS, MW, ADS, JLK, AMC, EMO, and ND had carried out clinical study and analyzed and interpreted clinical data. FS and MSR contributed to data collection, analysis, and interpretation of results, and writing the manuscript. All authors reviewed and contributed to writing the manuscript.
Corresponding authors
Ethics declarations
Competing interests
MSR reports grants or contracts from BMS, Janssen, Sanofi, and Heidelberg Pharma; Consulting fees from BMS, AMGEN, GSK, Janssen, Sanofi/Genzyme, Pfizer, AbbVie and Takeda; Support for attending meetings and/or travel from BMS, Janssen, Sanofi, Heidelberg Pharma; Participation on a Data Safety Monitoring Board or Advisory Board from AbbVie. YCC reports consulting fees from Janssen, GSK, Amgen and Takeda; Payment or honoraria from Janssen, Amgen, Takeda, Medison and Neopharm; Participation on a Data Safety Monitoring Board or Advisory Board from Janssen. FS reports grants or contracts from Celgene, Janssen, Oncopeptides, Sanofi, GSK and Targovax; Payment or honoraria from Amgen, BMS, Takeda, Abbvie, Janssen, Novartis, SkyliteDX, Oncopeptides, Sanofi, Pfizer, Daiki-Sankyo and GSK; Participation on a Data Safety Monitoring Board or Advisory Board from Abbvie, GSK, Celgene, Takeda, Janssen, Oncopeptides and Sanofi. AS, AMC and ND have no conflicts of interest to declare. MW reports all support for the present manuscript from Novartis; Grants or contracts from Roche; Consulting fees from Immatics, Boehringer, Imcheck and Novartis; Payment or honoraria from Novartis, Pfizer and Bristol Myers Squibb; Support for attending meetings and/or travel from AstraZeneca; Participation on a Data Safety Monitoring Board or Advisory Board from ISA Therapeutics. ADS reports clinical trial support from Takeda, Novartis, Regeneron, TeneoBio, Abbvie, Janssen, Sanofi, Prothena and Caelum; Consulting fees from Janssen and Prothena; Participation on Advisory Board from BMS and Janssen. JLK reports grants or contracts from Janssen, Abbvie, Genentech, Amgen, BMS, Novartis, Heidelberg Pharma AG, Fortis Therapeutics and Sutro Pharmaceuticals; Consulting fees from Abbvie, BMS and Genentech; Participation on a Data Safety Monitoring Board or Advisory Board from Abbvie and Incyte. EMO reports payment or honoraria from Janssen, BMS, Sanofi, GSK, Oncopeptides, Takeda, Pfizer and Amgen; Support for attending meetings and/or travel from GSK, Janssen and BMS; Participation on a Data Safety Monitoring Board or Advisory Board from Janssen, Sanofi, GSK, Takeda, Amgen, Oncopeptides, Pfizer, Karyopharm and BMS. AO, KH, PEJ, AF, LF and JPS are employees of Novartis. GT, AC, FCB are employees and stockholders of Novartis. BG, SDV, HL are employees and stockholders of Novartis; Novartis may own patents/patent applications related to the subject matter disclosed herein, on which they are listed as one of the inventors. KA is employee of Novartis; Novartis may own patents/patent applications related to the subject matter disclosed herein, on which I am listed as one of the inventors.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Raab, M.S., Cohen, Y.C., Schjesvold, F. et al. Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody. Leukemia 37, 1349–1360 (2023). https://doi.org/10.1038/s41375-023-01883-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-023-01883-3
- Springer Nature Limited